Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed): a guide to its use in older adults.

Scott LJ, Sanford M.

Drugs Aging. 2012 Oct;29(10):847-55. doi: 10.1007/s40266-012-0017-0. Review.

PMID:
23038610
2.

Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.

Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.

Vaccine. 2013 Aug 2;31(35):3594-602. doi: 10.1016/j.vaccine.2013.04.084. Epub 2013 May 18.

3.

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.

Jackson LA, Gurtman A, Rice K, Pauksens K, Greenberg RN, Jones TR, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.

Vaccine. 2013 Aug 2;31(35):3585-93. doi: 10.1016/j.vaccine.2013.05.010. Epub 2013 May 18.

4.

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.

Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.

Vaccine. 2013 Aug 2;31(35):3577-84. doi: 10.1016/j.vaccine.2013.04.085. Epub 2013 May 18.

5.

Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed): in older adults.

Sanford M.

Drugs. 2012 Jun 18;72(9):1243-55. doi: 10.2165/11209330-000000000-00000. Review.

PMID:
22686616
6.

Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [prevenar 13®].

Duggan ST.

Drugs. 2010 Oct 22;70(15):1973-86. doi: 10.2165/11205110-000000000-00000. Review.

PMID:
20883054
7.

13-valent pneumococcal conjugate vaccine: a review of its use in infants, children, and adolescents.

Plosker GL.

Paediatr Drugs. 2013 Oct;15(5):403-23. doi: 10.1007/s40272-013-0047-z. Review.

PMID:
24030738
8.

Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age.

Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.

Vaccine. 2014 Apr 25;32(20):2364-74. doi: 10.1016/j.vaccine.2014.02.002. Epub 2014 Mar 5.

PMID:
24606865
9.

Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized open-label trial.

Juergens C, de Villiers PJ, Moodley K, Jayawardene D, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.

Hum Vaccin Immunother. 2014;10(5):1343-53. doi: 10.4161/hv.27998. Epub 2014 Feb 27.

10.

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.

Esposito S, Tansey S, Thompson A, Razmpour A, Liang J, Jones TR, Ferrera G, Maida A, Bona G, Sabatini C, Pugni L, Emini EA, Gruber WC, Scott DA, Principi N.

Clin Vaccine Immunol. 2010 Jun;17(6):1017-26. doi: 10.1128/CVI.00062-10. Epub 2010 Apr 28.

11.

Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children.

Sigurdardottir ST, Center KJ, Davidsdottir K, Arason VA, Hjalmarsson B, Elisdottir R, Ingolfsdottir G, Northington R, Scott DA, Jonsdottir I.

Vaccine. 2014 Jan 9;32(3):417-24. doi: 10.1016/j.vaccine.2013.11.029. Epub 2013 Dec 2.

PMID:
24300594
12.

A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years.

Schwarz TF, Flamaing J, Rümke HC, Penzes J, Juergens C, Wenz A, Jayawardene D, Giardina P, Emini EA, Gruber WC, Schmoele-Thoma B.

Vaccine. 2011 Jul 18;29(32):5195-202. doi: 10.1016/j.vaccine.2011.05.031. Epub 2011 May 25.

13.

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers.

Yeh SH, Gurtman A, Hurley DC, Block SL, Schwartz RH, Patterson S, Jansen KU, Love J, Gruber WC, Emini EA, Scott DA; 004 Study Group.

Pediatrics. 2010 Sep;126(3):e493-505. doi: 10.1542/peds.2009-3027. Epub 2010 Aug 23.

PMID:
20732948
14.

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.

Vanderkooi OG, Scheifele DW, Girgenti D, Halperin SA, Patterson SD, Gruber WC, Emini EA, Scott DA, Kellner JD; Canadian PCV13 Study Group.

Pediatr Infect Dis J. 2012 Jan;31(1):72-7. doi: 10.1097/INF.0b013e318233049d.

PMID:
21960186
17.

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults.

Shiramoto M, Hanada R, Juergens C, Shoji Y, Yoshida M, Ballan B, Cooper D, Gruber WC, Scott DA, Schmoele-Thoma B.

Hum Vaccin Immunother. 2015;11(9):2198-206. doi: 10.1080/21645515.2015.1030550. Epub 2015 Jul 15.

18.

Antibody responses to polysaccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin disease.

Molrine DC, George S, Tarbell N, Mauch P, Diller L, Neuberg D, Shamberger RC, Anderson EL, Phillips NR, Kinsella K, Ambrosino DM.

Ann Intern Med. 1995 Dec 1;123(11):828-34.

PMID:
7486464
19.

Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn's disease.

Kantsø B, Halkjær SI, Thomsen OØ, Belard E, Gottschalck IB, Jørgensen CS, Krogfelt KA, Slotved HC, Ingels H, Petersen AM.

Vaccine. 2015 Oct 5;33(41):5464-9. doi: 10.1016/j.vaccine.2015.08.011. Epub 2015 Aug 12.

PMID:
26275480
20.

Development and clinical evaluation of Prevnar 13, a 13-valent pneumocococcal CRM197 conjugate vaccine.

Gruber WC, Scott DA, Emini EA.

Ann N Y Acad Sci. 2012 Aug;1263:15-26. doi: 10.1111/j.1749-6632.2012.06673.x. Epub 2012 Jul 25. Review.

PMID:
22830997
Items per page

Supplemental Content

Write to the Help Desk